Citations

Clear

9383 citation(s) found for "Thomas, PS".

Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation
Dispenzieri, Angela , Kyle, Robert A. , Lacy, Martha Q. , Burritt, Mary F., Therneau, Terry M. , McConnell, Joseph P., Litzow, Mark R. , Gastineau, Dennis A., Tefferi, Ayalew , Inwards, David J. , Micallef, Ivana N. , Ansell, Stephen M. , Porrata, Luis F. , Elliott, Michelle A. , Rajkumar, S. Vincent , Fonseca, Rafaël , Greipp, Philip R., Lust, John A., Zeldenrust, Steven R., Snow, Denise S., Hayman, S. R., McGregor, Christopher G.A. , Jaffe, Allan S. , Gertz, Morie A. , Hogan, William J. , Witzig, Thomas E. , Jaffe, Allan S. , Rajkumar, S Vincent , Dispenzieri, Angela , Fonseca, Rafael

Mayo Clinic

Blood | March 30, 2004 | Volume: 104 | Issue: 6 | Pages: 1881-1887

10.1182/blood-2004-01-0390 | PMID 15044258 Get It

AbstractPrimary systemic amyloidosis (AL) is a fatal plasma cell disorder. Pilot data suggest survival is better in patients undergoing peripheral blood stem cell transplantation (PBSCT), but the selection process makes the apparent benefit suspect. We have reported that circulating cardiac biomarkers are the best predictors of survival outside of the transplantation setting. We now test whether cardiac troponins (cTnT and cTnI) and N-terminal pro-brain natriuretic peptide (NT-proBNP) are prognostic in transplant recipients. In 98 patients with AL undergoing PBSCT, serum cardiac biomarkers were measured (cTnT, 98 patients; cTnI, 65 patients; and NT-proBNP, 63 patients). Elevated levels of cTnT, cTnI, and NT-proBNP were present in 14%, 43%, and 48% of patients, respectively. At 20 months median follow-up, median survival has not been reached for patients with values below the thresholds; in patients with values above the thresholds, median survival is 26.1 months, 66.1 months, and 66.1 months, respectively. Our previously reported risk systems incorporating these markers were also prognostic, notably the cTnT/NT-proBNP staging. Using this system, 49%, 38%, and 13% of patients were in stage I, stage II, and stage III, respectively. Determining levels of circulating biomarkers may be the most powerful tool for staging patients with AL undergoing PBSCT.
Activating FLT3 mutations in CD117/KIT+ T-cell acute lymphoblastic leukemias
Paietta, Elisabeth , Ferrando, Adolfo A. , Bennett, John M. , Racevskis, Janis, Dewald, Gordon W., Rowe, Jacob M. , Wiernik, Peter H. , Tallman, Martin S. , Look, A. Thomas , Neuberg, Donna , Lazarus, Hillard M.

Mayo Clinic

Blood | March 29, 2004 | Volume: 104 | Issue: 2 | Pages: 558-560

10.1182/blood-2004-01-0168 | PMID 15044257 Get It

Abstract Activating FLT3 mutations are the most common genetic aberrations in acute myeloid leukemia (AML), resulting in the constitutive activation of this receptor tyrosine kinase (RTK), but such mutations are rarely found in acute lymphoblastic leukemia (ALL). Here we describe a unique subset of de novo adult T-cell ALL (T-ALL) cases that coexpress CD117/KIT and cytoplasmic CD3 (CD117/KIT+ ALL). Activating mutations in the FLT3 RTK gene were found in each of 3 CD117/KIT+ cases that were analyzed, but not in 52 other adult T-ALL samples from the same series that lacked CD117/KIT expression. Our results indicate the need for clinical trials to test the efficacy of drugs that inhibit the FLT3 RTK in this subset of patients with T-ALL. (Blood. 2004;104:558-560)
Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study
Gordon, Leo I. , Molina, Arturo , Emmanouilides, Christos, Raubtischek, Andrew, Darif, Mohamed, Schilder, Russell J., Wiseman, G. , White, Christine A., Witzig, Thomas E. , Gordon, Leo I

Mayo Clinic

Blood | March 16, 2004 | Volume: 103 | Issue: 12 | Pages: 4429-4431

10.1182/blood-2003-11-3883 | PMID 15016644 Get It

Abstract We previously demonstrated that yttrium-90 (Y-90) ibritumomab tiuxetan (Zevalin) radioimmunotherapy (RIT) was safe and effective for relapsed or refractory CD20+, B-cell, non-Hodgkin lymphoma (NHL). We now provide long-term follow-up data in responding patients based on International Workshop Response Criteria. Complete (CR), CR unconfirmed (CRu), and partial response (PR) rates were 29%, 22%, and 22%, respectively (overall response rate 73%, 51% in CR/CRu). Mean time to progression (TTP) and duration of response (DR) in responders were 12.6 months and 11.7 months, respectively. At the maximum tolerated dose (0.4 mCi/kg [14.8 MBq/kg]), TTP and DR in complete responders (CR/CRu) were 28.3 and 27.5 months, respectively. Nine patients (24% of responding patients) had a TTP of more than 3 years. Long-term responders (> 5 years) have been identified. Ibritumomab tiuxetan produces durable responses in patients with indolent and diffuse large B-cell lymphoma. (Blood. 2004;103:4429-4431)
Disseminated Basidiobolomycosis in an Immunocompetent Woman
Bigliazzi, Caterina, Poletti, Venerino , Dell'Amore, D, Saragoni, Luca , Colby, Thomas V.

Mayo Clinic

Journal of Clinical Microbiology | March 5, 2004 | Volume: 42 | Issue: 3 | Pages: 1367-1369

10.1128/jcm.42.3.1367-1369.2004 | PMID 15004122 Get It

ABSTRACTBasidiobolomycosis is a chronic subcutaneous infection of the trunk and limbs due toBasidiobolus ranarum.The disease is well known in tropical areas, although recent cases of gastrointestinal basidiobolomycosis have also been reported in Arizona. We describe a young immunocompetent women who had presented with eosinophilia and lung infiltrates. She subsequently died, and diagnosis of disseminated basidiobolomycosis was made on the basis of histological features at autopsy.
Factor Structure of the Center for Epidemiologic Studies Depression Scale in Low- Income Women Attending Primary Care Clinics
Thomas, Janet , Brantley, Phillip J.

Mayo Clinic

European Journal of Psychological Assessment | March 3, 2004 | Volume: 20 | Issue: 2 | Pages: 106-115

10.1027/1015-5759.20.2.106 Get It

Given the high rates of major depressive disorder in primary care settings, routine use of screening measures to assist in identifying depressed individuals is warranted. The Center for Epidemiologic Studies Depression Scale (CES-D) ( Radloff, 1977 ) is a self-rated measure of distress commonly used to screen for depression in primary care settings. The present study was undertaken to confirm the original four-factor model in a sample of low-income women attending primary care clinics (N = 179). Although the original four-factor structure has been replicated in a variety of population groups, internal validity of the measure has not been previously examined in this population sample. A series of confirmatory factor analytic procedures failed to replicate the original four-factor structure or a second-order model. An exploratory analysis, using principal components and a VARIMAX rotation yielded three factors: Depressed Affect/Somatic Symptoms, Positive Affect, and Interpersonal Difficulties. Results of this study add support to previous research documenting an increased somatic presentation of depression in low-income samples. Implications for the use of the CES-D as a screening tool to identify depression in similar primary care samples are discussed.
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Recommendations for the Use of Laboratory Tests to Support Poisoned Patients Who Present to the Emergency Department
Wu, Alan H.B. , McKay, Charles, Broussard, Larry A. , Kwong, Tai C., Moyer, Thomas P. , Otten, Edward M., Welch, Shirley L., Wax, Paul M., Hoffman, Robert S.

Mayo Clinic

Clinical Chemistry | February 13, 2004 | Volume: 49 | Issue: 3 | Pages: 357-379

10.1373/49.3.357 | PMID 12600948 Get It

AbstractBackground: Exposure to drugs and toxins is a major cause for patients’ visits to the emergency department (ED).Methods: Recommendations for the use of clinical laboratory tests were prepared by an expert panel of analytical toxicologists and ED physicians specializing in clinical toxicology. These recommendations were posted on the world wide web and presented in open forum at several clinical chemistry and clinical toxicology meetings.Results: A menu of important stat serum and urine toxicology tests was prepared for clinical laboratories who provide clinical toxicology services. For drugs-of-abuse intoxication, most ED physicians do not rely on results of urine drug testing for emergent management decisions. This is in part because immunoassays, although rapid, have limitations in sensitivity and specificity and chromatographic assays, which are more definitive, are more labor-intensive. Ethyl alcohol is widely tested in the ED, and breath testing is a convenient procedure. Determinations made within the ED, however, require oversight by the clinical laboratory. Testing for toxic alcohols is needed, but rapid commercial assays are not available. The laboratory must provide stat assays for acetaminophen, salicylates, co-oximetry, cholinesterase, iron, and some therapeutic drugs, such as lithium and digoxin. Exposure to other heavy metals requires laboratory support for specimen collection but not for emergent testing.Conclusions:Improvements are needed for immunoassays, particularly for amphetamines, benzodiazepines, opioids, and tricyclic antidepressants. Assays for new drugs of abuse must also be developed to meet changing abuse patterns. As no clinical laboratory can provide services to meet all needs, the National Academy of Clinical Biochemistry Committee recommends establishment of regional centers for specialized toxicology testing.
Accuracy of detecting irregular cardiac rhythms via telemedicine
Zenk, Brenda M, Bratton, Robert L., Flipse, Thomas R, Page, E, Zenk, B.

Mayo Clinic

Journal of Telemedicine and Telecare | February 10, 2004 | Volume: 10 | Issue: 1 | Pages: 55-58

10.1258/135763304322764211 | PMID 15006218 Get It

We evaluated the accuracy of an electronic stethoscope in the detection of irregular cardiac rhythms. Ten patients with either normal sinus rhythm or atrial fibrillation previously documented by electrocardiogram (ECG) were recruited from a local retirement community. Six senior family medicine resident physicians were asked to assess the cardiac rhythms of the subjects as either regular or irregular, in both a telemedical and an in-person examination. An ECG was obtained simultaneously as the gold standard. Forty-five of the 60 in-person assessments were correct, as were 49 of the 60 telemedicine assessments. The difference was not significant. Physician confidence in telemedical examination did not affect the accuracy of examination. The results of this study suggest that telemedicine-directed auscultation of patients may be just as successful as inperson examination for the detection of cardiac arrhythmias.
Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study
Dispenzieri, Angela , Kyle, Robert A. , Lacy, Martha Q. , Therneau, Terry M. , Plevak, Matthew F., Rajkumar, S. Vincent , Fonseca, Rafaël , Greipp, Philip R., Lust, John A., Zeldenrust, Steven R., Snow, Denise S., Hayman, S. R., Litzow, Mark R. , Gastineau, Dennis A., Tefferi, Ayalew , Inwards, David J. , Micallef, Ivana N. , Ansell, Stephen M. , Porrata, Luis F. , Elliott, Michelle A. , Larson, Dirk R. , Witzig, Thomas E. , Gertz, Morie A. , Rajkumar, S Vincent , Dispenzieri, Angela , Fonseca, Rafael

Mayo Clinic

Blood | January 27, 2004 | Volume: 103 | Issue: 10 | Pages: 3960-3963

10.1182/blood-2003-12-4192 | PMID 14739213 Get It

AbstractPrimary systemic amyloidosis (AL) is a plasma cell dyscrasia resulting in multisystem failure and death. High-dose chemotherapy with peripheral blood stem cell transplantation (PBSCT) has been associated with higher response rates and seemingly higher overall survival than standard chemotherapy. Selection bias, however, confounds interpretation of these results. We performed a case-match-control study comparing overall survival of 63 AL patients undergoing transplantation with 63 patients not undergoing transplantation. Matching criteria included age, sex, time to presentation, left ventricular ejection fraction, serum creatinine, septal thickness, nerve involvement, 24-hour urine protein, and serum alkaline phosphatase. According to design, there was no difference between the groups with respect to sex (57% males), age (median, 53 years), left ventricular ejection fraction (65%), number of patients with peripheral nerve involvement (17%), cardiac interventricular septal wall thickness (12 mm), serum creatinine (1.1 mg/dL [97.24 μmol/L]), and bone marrow plasmacytosis (8%). Sixty-six patients have died (16 cases and 50 controls). For PBSCT and control groups, respectively, the 1-, 2-, and 4-year overall survival rates are 89% and 71%; 81% and 55%; and 71% and 41%. Outside a randomized clinical trial, these results present the strongest data supporting the role of PBSCT in selected patients with AL.
Immunoglobulin E and Eosinophil-Dependent Protective Immunity to LarvalOnchocerca volvulusin Mice Immunized with Irradiated Larvae
Abraham, David , Leon, Ofra, Schnyder‐Candrian, Silvia, Wang, Chun , Galioto, Ann Marie, Kerepesi, Laura A., Lee, James J. , Lustigman, Sara

Mayo Clinic

Infection and Immunity | January 24, 2004 | Volume: 72 | Issue: 2 | Pages: 810-817

10.1128/iai.72.2.810-817.2004 | PMID 14742524 Get It

ABSTRACTMice immunized with irradiatedOnchocerca volvulusthird-stage larvae developed protective immunity. Eosinophil levels were elevated in the parasite microenvironment at the time of larval killing, and measurements of total serum antibody levels revealed an increase in the immunoglobulin E (IgE) level in immunized mice. The goal of the present study was to identify the role of granulocytes and antibodies in the protective immune response to the larval stages ofO. volvulusin mice immunized with irradiated larvae. Immunity did not develop in mice if granulocytes, including both neutrophils and eosinophils, were eliminated, nor did it develop if only eosinophils were eliminated. Moreover, larvae were killed in naïve interleukin-5 transgenic mice, and the killing coincided with an increase in the number of eosinophils and the eosinophil peroxidase (EPO) level in the animals. To determine if EPO was required for protective immunity, mice that were genetically deficient in EPO were immunized, and there were no differences in the rates of parasite recovery in EPO-deficient mice and wild-type mice. Two mouse strains were used to study B-cell function; μMT mice lacked all mature B cells, and Xid mice had deficiencies in the B-1 cell population. Immunity did not develop in the μMT mice but did develop in the Xid mice. Finally, protective immunity was abolished in mice treated to eliminate IgE from the blood. We therefore concluded that IgE and eosinophils are required for adaptive protective immunity to larvalO. volvulusin mice.
Activation of Arterial Wall Dendritic Cells and Breakdown of Self-tolerance in Giant Cell Arteritis
Ma-Krupa, Wei, Jeon, Myung-Shin, Spoerl, Silvia , Tedder, Thomas F. , Goronzy, Jörg J. , Weyand, Cornelia M. , Jeon, Myung‐Shin , Goronzy, Jorg

Mayo Clinic

The Journal of Experimental Medicine | January 20, 2004 | Volume: 199 | Issue: 2 | Pages: 173-183

10.1084/jem.20030850 | PMID 14734523 Get It

Giant cell arteritis (GCA) is a granulomatous and occlusive vasculitis that causes blindness, stroke, and aortic aneurysm. CD4+ T cells are selectively activated in the adventitia of affected arteries. In human GCA artery–severe combined immunodeficiency (SCID) mouse chimeras, depletion of CD83+ dendritic cells (DCs) abrogated vasculitis, suggesting that DCs are critical antigen-presenting cells in GCA. Healthy medium-size arteries possessed an indigenous population of DCs at the adventitia–media border. Adoptive T cell transfer into temporal artery–SCID mouse chimeras demonstrated that DCs in healthy arteries were functionally immature, but gained T cell stimulatory capacity after injection of lipopolysaccharide. In patients with polymyalgia rheumatica (PMR), a subclinical variant of GCA, adventitial DCs were mature and produced the chemokines CCL19 and CCL21, but vasculitic infiltrates were lacking. Human histocompatibility leukocyte antigen class II–matched healthy arteries, PMR arteries, and GCA arteries were coimplanted into SCID mice. Immature DCs in healthy arteries failed to stimulate T cells, but DCs in PMR arteries could attract, retain, and activate T cells that originated from the GCA lesions. We propose that in situ maturation of DCs in the adventitia is an early event in the pathogenesis of GCA. Activation of adventitial DCs initiates and maintains T cell responses in the artery and breaks tissue tolerance in the perivascular space.